Can the Personalized Medicine Approach Contribute in Controlling Tuberculosis in General and India in Particular?

Overview

Journal Precis Clin Med

Publisher Oxford University Press

Specialty General Medicine

Date 2022 Jun 13

PMID 35694414

Authors

Nikhat Khan

Aparup Das

Affiliations

Soon will be listed here.

Abstract

Poor drug compliance and drug-resistant are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the -acetyl transferase-2-isoniazid (NAT2-INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.

Citing Articles

Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.

Sileshi T, Mekonen G, Makonnen E, Aklillu E Pharmgenomics Pers Med. 2022; 15:561-571.

PMID: 35693129 PMC: 9176238. DOI: 10.2147/PGPM.S363058.

References

Chatterjee S, Poonawala H, Jain Y . Drug-resistant tuberculosis: is India ready for the challenge?. BMJ Glob Health. 2018; 3(4):e000971. PMC: 6089296. DOI: 10.1136/bmjgh-2018-000971. View

Wang J, Tang S, Shen H . Association of genetic polymorphisms in the IL12-IFNG pathway with susceptibility to and prognosis of pulmonary tuberculosis in a Chinese population. Eur J Clin Microbiol Infect Dis. 2010; 29(10):1291-5. DOI: 10.1007/s10096-010-0985-0. View

Khan N, Pande V, Das A . NAT2 sequence polymorphisms and acetylation profiles in Indians. Pharmacogenomics. 2013; 14(3):289-303. DOI: 10.2217/pgs.13.2. View

Rao V, Bhat J, Yadav R, Muniyandi M, Sharma R, Bhondeley M . Pulmonary tuberculosis - a health problem amongst Saharia tribe in Madhya Pradesh. Indian J Med Res. 2015; 141(5):630-5. PMC: 4510762. DOI: 10.4103/0971-5916.159560. View

Wlodarska M, Johnston J, Gardy J, Tang P . A microbiological revolution meets an ancient disease: improving the management of tuberculosis with genomics. Clin Microbiol Rev. 2015; 28(2):523-39. PMC: 4402953. DOI: 10.1128/CMR.00124-14. View

Cordes H, Thiel C, Aschmann H, Baier V, Blank L, Kuepfer L . A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother. 2016; 60(10):6134-45. PMC: 5038291. DOI: 10.1128/AAC.00508-16. View

Garcia-Elorriaga G, Carrillo-Montes G, Mendoza-Aguilar M, Gonzalez-Bonilla C . Polymorphisms in tumor necrosis factor and lymphotoxin A in tuberculosis without and with response to treatment. Inflammation. 2010; 33(4):267-75. DOI: 10.1007/s10753-010-9181-8. View

Seung K, Keshavjee S, Rich M . Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015; 5(9):a017863. PMC: 4561400. DOI: 10.1101/cshperspect.a017863. View

Wang P, Pradhan K, Zhong X, Ma X . Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016; 6(5):384-392. PMC: 5045547. DOI: 10.1016/j.apsb.2016.07.014. View

10.

Alffenaar J, Akkerman O, Kim H, Tiberi S, Migliori G . Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. Int J Infect Dis. 2020; 92S:S5-S9. DOI: 10.1016/j.ijid.2020.01.041. View

11.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K . NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2012; 69(5):1091-101. PMC: 3641305. DOI: 10.1007/s00228-012-1429-9. View

12.

Joshi J . Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India. 2011; 28(3):193-200. PMC: 3162758. DOI: 10.4103/0970-2113.83977. View

13.

Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J . Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200(10):e93-e142. PMC: 6857485. DOI: 10.1164/rccm.201909-1874ST. View

14.

Prohaska A, Racimo F, Schork A, Sikora M, Stern A, Ilardo M . Human Disease Variation in the Light of Population Genomics. Cell. 2019; 177(1):115-131. DOI: 10.1016/j.cell.2019.01.052. View

15.

Olaru I, Lange C, Heyckendorf J . Personalized medicine for patients with MDR-TB. J Antimicrob Chemother. 2015; 71(4):852-5. DOI: 10.1093/jac/dkv354. View

16.

Doll M, Salazar-Gonzalez R, Bodduluri S, Hein D . Arylamine -acetyltransferase 2 genotype-dependent -acetylation of isoniazid in cryopreserved human hepatocytes. Acta Pharm Sin B. 2017; 7(4):517-522. PMC: 5518664. DOI: 10.1016/j.apsb.2017.05.003. View

17.

Zabost A, Brzezinska S, Kozinska M, Blachnio M, Jagodzinski J, Zwolska Z . Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int. 2014; 2013:853602. PMC: 3871508. DOI: 10.1155/2013/853602. View

18.

Aung A, Haas D, Hulgan T, Phillips E . Pharmacogenomics of antimicrobial agents. Pharmacogenomics. 2014; 15(15):1903-30. PMC: 4296903. DOI: 10.2217/pgs.14.147. View

19.

Alffenaar J, Gumbo T, Dooley K, Peloquin C, McIlleron H, Zagorski A . Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clin Infect Dis. 2019; 70(8):1774-1780. PMC: 7146003. DOI: 10.1093/cid/ciz942. View

20.

Png E, Alisjahbana B, Sahiratmadja E, Marzuki S, Nelwan R, Balabanova Y . A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. BMC Med Genet. 2012; 13:5. PMC: 3287960. DOI: 10.1186/1471-2350-13-5. View